Wugen to Present at the Innate Killer Summit 2022

The details of Wugen’s fireside chat and presentation are as follows:

• Format: Industry Leader’s Fireside Chat
  Presenter: Dan Kemp, Ph.D., President and Chief Executive Officer, Wugen
  Date & Time: Thursday, March 31, 2022 at 8:15 a.m. PT

• Format: Presentation titled “Characterizing an Ideal NK Cell Phenotype Leveraging Assays to Indicate Therapeutic Benefit”
  Presenter: Ayman Kabakibi, Ph.D., Chief Operating Officer & Executive Vice President, Research & Development, Wugen
  Date & Time: Thursday, March 31, 2022 at 11:30 a.m. PT

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary Moneta^TM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta^TM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005008/en/